Market closed
Karyopharm Therapeutics/$KPTI
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Ticker
$KPTI
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
325
Website
KPTI Metrics
BasicAdvanced
$83M
-
-$1.08
0.15
-
Price and volume
Market cap
$83M
Beta
0.15
52-week high
$1.95
52-week low
$0.58
Average daily volume
996K
Financial strength
Current ratio
3.004
Quick ratio
2.688
Long term debt to equity
-165.422
Total debt to equity
-167.719
Interest coverage (TTM)
-3.88%
Management effectiveness
Return on assets (TTM)
-34.27%
Return on equity (TTM)
67.28%
Valuation
Price to revenue (TTM)
0.53
Price to book
-0.52
Price to tangible book (TTM)
-0.52
Price to free cash flow (TTM)
-0.653
Growth
Revenue change (TTM)
1.77%
Earnings per share change (TTM)
-16.77%
3-year revenue growth (CAGR)
7.75%
3-year earnings per share growth (CAGR)
-26.85%
What the Analysts think about KPTI
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Karyopharm Therapeutics stock.
KPTI Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
KPTI Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
KPTI News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Karyopharm Therapeutics stock?
Karyopharm Therapeutics (KPTI) has a market cap of $83M as of January 31, 2025.
What is the P/E ratio for Karyopharm Therapeutics stock?
The price to earnings (P/E) ratio for Karyopharm Therapeutics (KPTI) stock is 0 as of January 31, 2025.
Does Karyopharm Therapeutics stock pay dividends?
No, Karyopharm Therapeutics (KPTI) stock does not pay dividends to its shareholders as of January 31, 2025.
When is the next Karyopharm Therapeutics dividend payment date?
Karyopharm Therapeutics (KPTI) stock does not pay dividends to its shareholders.
What is the beta indicator for Karyopharm Therapeutics?
Karyopharm Therapeutics (KPTI) has a beta rating of 0.15. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.